PHARMACOECONOMIC REVIEW OF INTERNATIONAL STUDIES OF HERCEPTIN-BASED TREATMENT FOR HER2-POSITIVE BREAST CANCER
Herceptin is human monoclonal antibody, which selectively interacts with extracellular domain of human epidermal growth factor receptors 2 (HER2). Herceptin has been proven to be effective and safe in treatment for HER2-positive breast cancer in early and metastatic stages in different treatment strategies (adjuvant, neoadjuvant, combined therapy, monotherapy). Pharmacoeconomic analysis of Herceptin-based treatment for HER2-positive breast cancer in early and metastatic stages by using different methods supports making a conclusion of the cost-effectiveness of Herceptin, which is comparable with or better than other widely used cancer and non-cancer therapies.